Oprelvekin

Interleukin eleven (IL-11) is a thrombopoietic growth factor that directly stimulates the proliferation of hematopoietic stem cells and megakaryocyte progenitor cells and induces megakaryocyte maturation resulting in increased platelet production. IL-11 is a member of a family of human growth factors which includes human growth hormone, granulocyte colonystimulating factor (G-CSF), and other growth factors. Oprelvekin, is produced in Escherichia coli (E. coli) by recombinant DNA technology. oprelveki is polypeptide with 177 amino acids in length and differs from the 178 amino acid length of native IL-11 only in lacking the amino-terminal proline residue. This alteration has not resulted in measurable differences in bioactivity either in vitro or in vivo.

Brands
GENEPLATE GENEPLATE
Adult Dose
Neonatal
Paedriatic
Characteristics
Oprelvekin also known as AGIF, AGIF, AGIF. . It is of Synthetic origin and belongs to non-glycosylate. .
Contraindications
Oprelvekin
Effects
The severe or irreversible adverse effects of Oprelvekin, which give rise to further complications include Fever, Atrial fibrillation, Syncope, Pneumonia, neutropenic fever.The symptomatic adverse reactions produced by Oprelvekin are more or less tolerable and if they become severe, they can be treated symptomatically, these include Palpitation, Tachycardia, Conjunctival irritation, Edema, Pleural effusion, Dypnoea, Tachycardia, atrial arrhythmia, pleural effusion.
Indications
Oprelvekin is primarily indicated in conditions like Thrombocytopenia.
Interactions
No data regarding the interactions of Oprelvekin was found.
Interfrence
Risks
Drug should not be given to Paediatrics, Pregnant Mothers, Cardiac / Hypertensive Patients, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
injection Do not Freeze. Protect from Sunlight.
Warnings
Allergic Reactions Including Anaphylaxis, Increased Toxicity Following Myeloablative Therapy, fluid retention, Dilutional Anemia, arrhythmias and pulmonary edema,Papilledema, Patients with a history of stroke or transient ischemic attack may also be at increased risk
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.